• Jefferies initiated coverage of Moderna, Inc. (NASDAQ: MRNA) with a "Hold" rating and a stock price of $29.62.
• Amundi reduced its stake in Moderna by 31.9%, selling 425,861 shares.
• Other investment firms, including Natixis Advisors LLC and Charles Schwab Investment Management Inc., have increased their holdings in Moderna.

Moderna, Inc. (NASDAQ: MRNA) is a biotechnology company known for its work in developing mRNA-based vaccines and therapeutics. The company gained significant attention during the COVID-19 pandemic for its vaccine. As of December 11, 2025, Jefferies initiated coverage of Moderna with a "Hold" rating, and the stock was priced at $29.62, as reported by TheFly.

Amundi, a major investment firm, has reduced its stake in Moderna by 31.9% in the recent quarter. This reduction involved selling 425,861 shares, leaving Amundi with 909,429 shares valued at $27.5 million. This move indicates a shift in Amundi's investment strategy regarding Moderna.

In contrast, other investment firms have increased their holdings in Moderna. Natixis Advisors LLC raised its stake by 70.7% in the first quarter, now holding 17,761 shares valued at $504,000. Similarly, Charles Schwab Investment Management Inc. increased its holdings by 12.2%, now owning 2,629,865 shares worth $74.6 million.

Moderna's stock price has shown some volatility, with a current price of $29.62, reflecting a 2.03% increase. The stock has fluctuated between $28.87 and $29.66 today. Over the past year, it reached a high of $48.92 and a low of $22.28, indicating significant price movement.

The company's market capitalization is approximately $11.57 billion, and the trading volume for the day is 7,159,436 shares on the NASDAQ exchange. These figures highlight the active trading and investor interest in Moderna's stock.